About Us

Corporate Overview

Bridge Laboratories is a preclinical contract research organization (CRO) that provides US-level regulatory-compliant drug development services globally. Bridge is US owned and headquartered in Gaithersburg, Maryland, with lab facilities in both the US and Beijing, China. Bridge is known for its extensive work in toxicology, including vaccines, developmental and reproductive toxicology (DART), and safety pharmacology. The company's AAALAC-accredited facility in China was among the first labs to perform GLP studies for clients worldwide.

Preclinical Services Portfolio

At Bridge, we help our clients plan and conduct safety assessment studies to support compound development programs involving small molecules, biologics, neutraceuticals, vaccines, chemicals and intermediates. We conduct both short- and long-term in vivo studies employing everything from acute to carcinogenicity protocols.

GLP-Compliant Services — general toxicology, DART, safety pharmacology (CV, CNS, respiratory), vaccine development, pathology, bioanalytical, and DMPK
Species — mice, rats, rabbits, guinea pigs, canines, non-human primates, and minipigs
Routes of Administration — continuous infusion, dermal, ocular, oral (gavage, capsule, diet, drinking water, etc.), parenteral (I.V., I.M., S.C., I.P., etc.), vaginal, rectal and customized.

Fully Accredited US and China Facilities

Bridge is one of the first preclinical CROs to offer its clients a choice of US- or China-based drug development services. Both our 90,000 square-foot Gaithersburg, Maryland and 84,000 square-foot Beijing, China sites are globally integrated:

Equivalent SOPs – English only
Integrated program management
US board-certified toxicologists and pathologists
Global accreditations – GLP-compliant and AAALAC-accredited (both the US and China); in addition, the US is USDA-registered with OLAW assurance and DEA and radiation licenses.
Animal welfare procedures
Strict confidentiality and data security
The industry’s top staff technical training and certification program

Highly Qualified, Experienced Staff

Bridge Laboratories has a hard-earned reputation for superior technical expertise, extensive regulatory experience and remarkable speed and flexibility in meeting the needs of its clients. In 2007, for example, we achieved a 98.9% on-time or early report delivery rate in the US and 100% in China. We have been delivering outstanding results to our clients for over 16 years – and it all starts with the quality of our staff. Some 80% of our Study Directors have PhDs and are board-certified Toxicologists. All of them are leading scientists at the top of their fields, with an average of 15 years experience. And all share the same client-centered focus and “can do” attitude that extends to every member of the Bridge team and drives every Bridge research project.

The Bridge Advantage: More Choices, Better Service

The choice of either US- or China-based drug development services that Bridge offers its clients is a major advantage to organizations whose research relies on non-human primates or who must, for other reasons, leverage the economies of doing business in the China market. No matter which approach you take, however, you can be sure of getting the same high-quality services from a drug development partner committed to delivering your research study or other regulatory submission on time, at a competitive price.